Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results — TradingView News
Gilead Sciences, Inc., a biopharmaceutical company, has reported its financial performance for the fourth quarter and the entirety of 2025. The company’s results indicate strong performance across key areas, reflecting its established position in the market and ongoing strategic efforts.
Financial Performance
Total revenues for the fourth quarter of 2025 reached $7.9 billion, a 5% increase compared to the same period in 2024. This growth was largely fueled by increased sales of HIV and Liver Disease treatments, though partially offset by decreased sales of Veklury. Diluted earnings per share (EPS) for the quarter were $1.74, an increase from $1.42 in the fourth quarter of 2024, attributed to higher income tax benefits, gains from equity securities, and increased product sales.
Non-GAAP diluted EPS was $1.86 for the quarter, slightly lower than the $1.90 reported in the same period of 2024, due to increased expenses related to acquired in-process research and development. For the full year 2025, total revenues increased by 2% to $29.4 billion, with product sales excluding Veklury growing by 4% to $28.0 billion. Full-year diluted EPS was $6.78, a significant increase from $0.38 in 2024.
Business and Operational Highlights
HIV product sales for the full year 2025 increased by 6% to $20.8 billion, driven by demand for both treatment and prevention options. Biktarvy sales increased by 7% to $14.3 billion, and Descovy sales surged by 31% to $2.8 billion. The Liver Disease portfolio also saw a 6% increase in sales, reaching $3.2 billion, due to increased demand for Livdelzi and other hepatitis treatments.
However, Veklury sales decreased by 49% to $911 million, reflecting a decline in COVID-19 hospitalizations. Cell Therapy product sales decreased by 7% to $1.8 billion, facing competitive challenges.
Strategic Developments
During the fourth quarter, Gilead generated $3.3 billion in operating cash flow, distributed $1.0 billion in dividends, and repurchased $230 million of its common stock. The company also announced the acquisition of Interius BioTherapeutics and ongoing collaborations with Shenzhen Pregene Biopharma and LEO Pharma.
Gilead’s Board of Directors has declared a quarterly dividend of $0.82 per share, payable on March 30, 2026.
According to Daniel O’Day, Chairman and CEO of Gilead, the company’s strong performance and the successful launch of Yeztugo position it well for future growth. He anticipates potential launches in 2026, including two cancer therapies and an additional HIV treatment option.
Looking Ahead
Gilead anticipates product sales between $29.6 billion and $30.0 billion for the full year 2026. Non-GAAP diluted EPS is projected to be between $8.45 and $8.85. The company remains focused on expanding its product offerings and increasing its impact on healthcare.
Frequently Asked Questions
What drove Gilead’s revenue increase in Q4 2025?
A 5% increase in total revenues for Q4 2025 was primarily driven by higher sales of HIV and Liver Disease products.
What happened to Veklury sales in 2025?
Veklury sales declined by 49% to $911 million, reflecting lower COVID-19-related hospitalizations.
What is Gilead’s outlook for 2026?
Gilead expects product sales to range between $29.6 billion and $30.0 billion for the full year 2026, with non-GAAP diluted EPS projected between $8.45 and $8.85.
As Gilead continues to navigate a changing healthcare landscape, how might its strategic initiatives shape the future of treatment and prevention for HIV, liver disease, and cancer?